Search Results - "Juan Luis Steegmann"

Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner by Kreutzman, Anna, Colom-Fernández, Beatriz, Jiménez, Ana Marcos, Ilander, Mette, Cuesta-Mateos, Carlos, Pérez-García, Yaiza, Arévalo, Cristina Delgado, Brück, Oscar, Hakanen, Henna, Saarela, Jani, Ortega-Carrión, Alvaro, de Rosendo, Ana, Juanes-García, Alba, Steegmann, Juan Luis, Mustjoki, Satu, Vicente-Manzanares, Miguel, Muñoz-Calleja, Cecilia

“…Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very…”
Get full text

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea by Alvarez-Larrán, Alberto, Pérez-Encinas, Manuel, Ferrer-Marín, Francisca, Hernández-Boluda, Juan Carlos, Ramírez, María José, Martínez-López, Joaquín, Magro, Elena, Cruz, Yasmina, Mata, María Isabel, Aragües, Pilar, Fox, María Laura, Cuevas, Beatriz, Montesdeoca, Sara, Hernández-Rivas, José Angel, García-Gutiérrez, Valentín, Gómez-Casares, María Teresa, Steegmann, Juan Luis, Durán, María Antonia, Gómez, Montse, Kerguelen, Ana, Bárez, Abelardo, García, Mari Carmen, Boqué, Concepción, Raya, José María, Martínez, Clara, Albors, Manuel, García, Francesc, Burgaleta, Carmen, Besses, Carlos

“…Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved…”
Get full text

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet by Guilhot, Joëlle, Baccarani, Michele, Clark, Richard E., Cervantes, Francisco, Guilhot, François, Hochhaus, Andreas, Kulikov, Sergei, Mayer, Jiri, Petzer, Andreas L., Rosti, Gianantonio, Rousselot, Philippe, Saglio, Giuseppe, Saussele, Susanne, Simonsson, Bengt, Steegmann, Juan-Luis, Zaritskey, Andrey, Hehlmann, Rüdiger

“…The treatment policy of chronic myeloid leukemia (CML), particularly with tyrosine kinase inhibitors, has been influenced by several recent studies that were…”
Get full text

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase by Alonso-Dominguez, Juan M, Casado, Luis Felipe, Anguita, Eduardo, Gomez-Casares, Maria Teresa, Buño, Ismael, Ferrer-Marín, Francisca, Arenas, Alicia, Del Orbe, Rafael, Ayala, Rosa, Llamas, Pilar, Salgado, Rocio N, Osorio, Santiago, Sanchez-Godoy, Pedro, Burgaleta, Carmen, Mahíllo-Fernández, Ignacio, Garcia-Gutierrez, Valentin, Steegmann, Juan Luis, Martinez-Lopez, Joaquín

“…Patched homolog 1 gene (PTCH1) expression and the ratio of PTCH1 to Smoothened (SMO) expression have been proposed as prognostic markers of the response of…”
Get full text

Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients by Colom-Fernández, Beatriz, Kreutzman, Anna, Marcos-Jiménez, Ana, García-Gutiérrez, Valentín, Cuesta-Mateos, Carlos, Portero-Sainz, Itxaso, Pérez-García, Yaiza, Casado, Luis Felipe, Sánchez-Guijo, Fermín, Martínez-López, Joaquín, Ayala, Rosa M, Boqué, Concha, Xicoy, Blanca, Montero, Isabel, Soto, César, Paz, Raquel, Silva, Gabriela, Vega-Piris, Lorena, Steegmann, Juan Luis, Muñoz-Calleja, Cecilia

“…Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In…”
Get full text

Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase by Cuesta-Domínguez, Álvaro, Ortega, Mara, Ormazábal, Cristina, Santos-Roncero, Matilde, Galán-Díez, Marta, Steegmann, Juan Luis, Figuera, Ángela, Arranz, Eva, Vizmanos, José Luis, Bueren, Juan A, Río, Paula, Fernández-Ruiz, Elena

“…Chromosomal translocations in tumors frequently produce fusion genes coding for chimeric proteins with a key role in oncogenesis. Recent reports described a…”
Get full text

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) by Jabbour, Elias, Kantarjian, Hagop M., Saglio, Giuseppe, Steegmann, Juan Luis, Shah, Neil P., Boqué, Concepción, Chuah, Charles, Pavlovsky, Carolina, Mayer, Jiří, Cortes, Jorge, Baccarani, Michele, Kim, Dong-Wook, Bradley-Garelik, M. Brigid, Mohamed, Hesham, Wildgust, Mark, Hochhaus, Andreas

“…This analysis explores the impact of early cytogenetic and molecular responses on the outcomes of patients with chronic myeloid leukemia in chronic phase…”
Get full text

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 by Baccarani, Michele, Deininger, Michael W., Rosti, Gianantonio, Hochhaus, Andreas, Soverini, Simona, Apperley, Jane F., Cervantes, Francisco, Clark, Richard E., Cortes, Jorge E., Guilhot, François, Hjorth-Hansen, Henrik, Hughes, Timothy P., Kantarjian, Hagop M., Kim, Dong-Wook, Larson, Richard A., Lipton, Jeffrey H., Mahon, François-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Pane, Fabrizio, Radich, Jerald P., Rousselot, Philippe, Saglio, Giuseppe, Saußele, Susanne, Schiffer, Charles, Silver, Richard, Simonsson, Bengt, Steegmann, Juan-Luis, Goldman, John M., Hehlmann, Rüdiger

“…Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A…”
Get full text

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia by Steegmann, Juan Luis, Cervantes, Francisco, le Coutre, Philipp, Porkka, Kimmo, Saglio, Giuseppe

“…Abstract In patients with chronic myeloid leukemia (CML), use of the BCR-ABL1-specific tyrosine kinase inhibitors (TKIs) imatinib, nilotinib and dasatinib has…”
Get full text

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study by Giles, Francis J, Rosti, Gianantonio, Beris, Photis, Clark, Richard E, le Coutre, Philipp, Mahon, Francois-Xavier, Steegmann, Juan-Luis, Valent, Peter, Saglio, Giuseppe

“…Nilotinib (Tasigna(®)) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinib's deficiencies. Nilotinib has significant…”
Get more information

Cardiovascular and pulmonary adverse events in patients treated with BCR‐ABL inhibitors: Data from the FDA Adverse Event Reporting System by Cortes, Jorge, Mauro, Michael, Steegmann, Juan Luis, Saglio, Giuseppe, Malhotra, Rachpal, Ukropec, Jon A., Wallis, Nicola T.

“…Rare but serious cardiovascular and pulmonary adverse events (AEs) have been reported in patients with chronic myeloid leukemia treated with BCR‐ABL…”
Get full text

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months by Casado, Luis‐Felipe, García‐Gutiérrez, José‐Valentín, Massagué, Isabel, Giraldo, Pilar, Pérez‐Encinas, Manuel, Paz, Raquel, Martínez‐López, Joaquín, Bautista, Guiomar, Osorio, Santiago, Requena, María‐José, Palomera, Luis, Peñarrubia, María‐Jesús, Calle, Carmen, Hernández‐Rivas, José‐Ángel, Burgaleta, Carmen, Maestro, Begoña, García‐Ormeña, Nuria, Steegmann, Juan‐Luis

“…Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic…”
Get full text

Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection by Vigón, Lorena, Rodríguez-Mora, Sara, Luna, Alejandro, Sandonís, Virginia, Mateos, Elena, Bautista, Guiomar, Steegmann, Juan Luis, Climent, Nuria, Plana, Montserrat, Pérez-Romero, Pilar, de Ory, Fernando, Alcamí, José, García-Gutierrez, Valentín, Planelles, Vicente, López-Huertas, María Rosa, Coiras, Mayte

“…[Display omitted] Tyrosine kinase inhibitors (TKIs) are successfully used in clinic to treat chronic myeloid leukemia (CML). Our group previously described…”
Get full text

Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors by Bermejo, Mercedes, Ambrosioni, Juan, Bautista, Guiomar, Climent, Núria, Mateos, Elena, Rovira, Cristina, Rodríguez-Mora, Sara, López-Huertas, María Rosa, García-Gutiérrez, Valentín, Steegmann, Juan Luis, Duarte, Rafael, Cervantes, Francisco, Plana, Montserrat, Miró, José M., Alcamí, José, Coiras, Mayte

“…Mechanismsof actionof different TKIs for avoiding HIV-1 infection of CD4+ T lymphocytes. 1) Preventing SAMHD1 phosphorylation; 2) impeding TCR-mediated…”
Get full text

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis by Hernández‐Boluda, Juan‐Carlos, Pastor‐Galán, Irene, Arellano‐Rodrigo, Eduardo, Raya, José‐María, Pérez‐Encinas, Manuel, Ayala, Rosa, Ferrer‐Marín, Francisca, Velez, Patricia, Mora, Elvira, Fox, María‐Laura, Hernández‐Rivas, Jesús‐María, Xicoy, Blanca, Mata‐Vázquez, María‐Isabel, García‐Fortes, María, Pérez‐López, Raúl, Angona, Anna, Cuevas, Beatriz, Senín, Alicia, Ramírez, María‐José, Ramírez‐Payer, Angel, Gómez‐Casares, María‐Teresa, Martínez‐Valverde, Clara, Magro, Elena, Steegmann, Juan‐Luis, Durán, María‐Antonia, García‐Hernández, Carmen, Gasior, Mercedes, Villambrosia, Sonia González, Alvarez‐Larrán, Alberto, Pereira, Arturo

“…Summary Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We…”
Get full text

Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response by Cervantes, Francisco, Correa, Juan-Gonzalo, Pérez, Isabel, García-Gutiérrez, Valentín, Redondo, Sara, Colomer, Dolors, Jiménez-Velasco, Antonio, Steegmann, Juan-Luis, Sánchez-Guijo, Fermín, Ferrer-Marín, Francisca, Pereira, Arturo, Osorio, Santiago

“…To determine whether a lower imatinib dose could minimize toxicity while maintaining the molecular response (MR), imatinib dose was reduced to 300 mg daily in…”
Get full text

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis by Giles, Francis J., Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C. P., Steegmann, Juan Luis, Griskevicius, Laimonas, le Coutre, Philipp, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Saussele, Susanne, Hellmann, Andrzej, Koskenvesa, Perttu, Brümmendorf, Tim H., Gastl, Gunther, Castagnetti, Fausto, Vincenzi, Beatrice, Haenig, Jens, Hochhaus, Andreas

“…Purpose Achievement of deep molecular response with a tyrosine kinase inhibitor in patients with chronic myeloid leukemia (CML) is required to attempt…”
Get full text

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? by Osorio, Santiago, Escudero-Vilaplana, Vicente, Gómez-Centurión, Ignacio, Pérez-López, Raúl, Ayala, Rosa, Vall-Llovera, Ferrán, García-Gutierrez, Valentín, Gómez Casares, María Teresa, González San Miguel, José David, Hernández-Rivas, José-Ángel, Sánchez-Guijo, Fermín, Martínez-García, Ana Belén, Villalón, Lucia, Conesa-García, Venancio, Rodriguez, Alicia, Casado, Felipe, Garcia-Gonzalez, Xandra, Sáez Perdomo, María Nieves, Baños, Úrsula, Steegmann, Juan Luis

“…With tyrosine kinase inhibitors (TKI), chronic myeloid leukemia (CML) patients are achieving similar rates of survival to the general population and some…”
Get full text

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients by Hernández-Boluda, Juan Carlos, Pereira, Arturo, Pastor-Galán, Irene, Alvarez-Larrán, Alberto, Savchuk, Alisa, Puerta, José Manuel, Sánchez-Pina, José María, Collado, Rosa, Díaz-González, Alvaro, Angona, Anna, Sagüés, Miguel, García-Gutiérrez, Valentín, Boqué, Concepción, Osorio, Santiago, Vallansot, Rolando, Palomera, Luis, Mendizábal, Arantxa, Casado, Luis Felipe, Pérez-Encinas, Manuel, Pérez-López, Raúl, Ferrer-Marín, Francisca, Sánchez-Guijo, Fermín, García, Carmen, Heras, Natalia de las, López-Lorenzo, José Luis, Cervantes, Francisco, Steegmann, Juan Luis

“…Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular response (MMR) after stopping treatment with…”
Get full text

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients by García-Gutiérrez, Valentín, Milojkovic, Dragana, Hernandez-Boluda, Juan Carlos, Claudiani, Simone, Martin Mateos, María Luisa, Casado-Montero, Luis Felipe, González, Gloria, Jimenez-Velasco, Antonio, Boque, Concepcion, Martinez-Trillos, Alejandra, Vázquez, Isabel Mata, Payer, Ángel Ramírez, Senín, Alicia, Amustio Díez, Elena, García, Abelardo Bárez, Carrascosa, Guiomar Bautista, Ortí, Guillermo, Ruiz, Beatriz Cuevas, Fernández, Maria Ángeles, del Carmen García Garay, María, Giraldo, Pilar, Guinea, Jose María, De Las Heras Rodríguez, Natalia, Hernán, Nuria, Pérez, Ana Iglesias, Piris-Villaespesa, Miguel, Lorenzo, Jose Luis López, Martí-Tutusaus, Josep Maria Martí, Vallansot, Rolando Omar, Ortega Rivas, Fernando, Puerta, Jose Manuel, Ramirez, Maria Jose, Romero, Esperanza, Romo, Andres, Rosell, Ana, Saavedra, Silvanna Saavedra, Sebrango, Ana, Tallon, José, Valencia, Sandra, Portero, Angeles, Steegmann, Juan Luis

“…Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid…”
Get full text